1. Home
  2. VRN vs APLS Comparison

VRN vs APLS Comparison

Compare VRN & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRN
  • APLS
  • Stock Information
  • Founded
  • VRN 1994
  • APLS 2009
  • Country
  • VRN Canada
  • APLS United States
  • Employees
  • VRN N/A
  • APLS N/A
  • Industry
  • VRN Oil & Gas Production
  • APLS Biotechnology: Pharmaceutical Preparations
  • Sector
  • VRN Energy
  • APLS Health Care
  • Exchange
  • VRN Nasdaq
  • APLS Nasdaq
  • Market Cap
  • VRN 4.3B
  • APLS 4.4B
  • IPO Year
  • VRN N/A
  • APLS 2017
  • Fundamental
  • Price
  • VRN $5.43
  • APLS $30.77
  • Analyst Decision
  • VRN Strong Buy
  • APLS Buy
  • Analyst Count
  • VRN 2
  • APLS 19
  • Target Price
  • VRN $11.50
  • APLS $49.89
  • AVG Volume (30 Days)
  • VRN 7.3M
  • APLS 4.1M
  • Earning Date
  • VRN 10-31-2024
  • APLS 11-05-2024
  • Dividend Yield
  • VRN 6.08%
  • APLS N/A
  • EPS Growth
  • VRN N/A
  • APLS N/A
  • EPS
  • VRN 1.31
  • APLS N/A
  • Revenue
  • VRN $2,851,178,799.00
  • APLS $715,216,000.00
  • Revenue This Year
  • VRN $34.64
  • APLS $95.59
  • Revenue Next Year
  • VRN $0.28
  • APLS $13.77
  • P/E Ratio
  • VRN $4.14
  • APLS N/A
  • Revenue Growth
  • VRN 23.15
  • APLS 162.10
  • 52 Week Low
  • VRN $4.90
  • APLS $24.34
  • 52 Week High
  • VRN $9.28
  • APLS $73.80
  • Technical
  • Relative Strength Index (RSI)
  • VRN 45.19
  • APLS 59.23
  • Support Level
  • VRN $5.19
  • APLS $26.62
  • Resistance Level
  • VRN $5.55
  • APLS $30.80
  • Average True Range (ATR)
  • VRN 0.15
  • APLS 1.88
  • MACD
  • VRN 0.06
  • APLS 0.24
  • Stochastic Oscillator
  • VRN 77.27
  • APLS 96.69

About VRN Veren Inc. Common shares

Veren Inc is an oil producer company. It is engaged in acquiring, developing, and holding interests in petroleum assets operations across western Canada.

About APLS Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Share on Social Networks: